We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+17.46%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$1.94B
AUM Growth
+$209M
Cap. Flow
+$157M
Cap. Flow %
8.08%
Top 10 Hldgs %
37.79%
Holding
268
New
72
Increased
34
Reduced
55
Closed
76

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$16.3M
2
SONX
Sonendo, Inc.
SONX
+$7.34M
3
NTRA icon
Natera
NTRA
+$6.8M
4
AZTA icon
Azenta
AZTA
+$6.45M
5
QTRX icon
Quanterix
QTRX
+$5.89M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$22.4M
2
ILMN icon
Illumina
ILMN
+$11.7M
3
AZN icon
AstraZeneca
AZN
+$9.6M
4
OM icon
Outset Medical
OM
+$8.46M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.3M

Sector Composition

Rank Sector Weight
1 Healthcare 27.35%
2 Industrials 0.25%
3 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVDL
126
DELISTED
Avadel Pharmaceuticals
AVDL
$1.86M 0.1%
260,000
+174,242
+203% +$1.22M
SKIN icon
127
PUT
SkinHealth Systems
SKIN
$84.2M
$1.82M 0.09%
+200,000
New +$2.16M
ESTA icon
128
CALL
Establishment Labs
ESTA
$2.25B
$1.64M 0.08%
25,000
-48,600
-66% -$2.94M
ANNX icon
129
Annexon
ANNX
$873M
$1.57M 0.08%
302,734
-71,896
-19% -$395K
SOPH icon
130
SOPHiA GENETICS
SOPH
$635M
$1.55M 0.08%
754,036
-142,204
-16% -$319K
GHRS icon
131
GH Research
GHRS
$2.08B
$1.54M 0.08%
158,327
– –
GERN icon
132
PUT
Geron
GERN
$1.01B
$1.51M 0.08%
623,300
– –
MIST icon
133
Milestone Pharmaceuticals
MIST
$141M
$1.47M 0.08%
371,788
-224,743
-38% -$1.18M
HZNP
134
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$1.47M 0.08%
12,900
– –
SEER icon
135
PUT
Seer Inc
SEER
$118M
$1.45M 0.07%
+250,000
New +$1.69M
APYX icon
136
Apyx Medical
APYX
$126M
$1.42M 0.07%
607,560
-900,502
-60% -$2.75M
RXDX
137
PUT
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$1.38M 0.07%
12,500
– –
LQDA icon
138
Liquidia Corp
LQDA
$7.01B
$1.33M 0.07%
208,535
-329,335
-61% -$1.77M
ALKS icon
139
Alkermes
ALKS
$8.44B
$1.31M 0.07%
50,000
– –
BCRX icon
140
BioCryst Pharmaceuticals
BCRX
$2.71B
$1.22M 0.06%
106,629
-170,000
-61% -$2.12M
CNCE
141
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$1.21M 0.06%
+206,525
New +$1.09M
EXEL icon
142
Exelixis
EXEL
$12.5B
$1.2M 0.06%
75,000
– –
ADMA icon
143
ADMA Biologics
ADMA
$2.19B
$1.16M 0.06%
+300,000
New +$925K
VRDN icon
144
Viridian Therapeutics
VRDN
$2.59B
$1.02M 0.05%
35,003
-40,000
-53% -$922K
SMMT icon
145
CALL
Summit Therapeutics
SMMT
$12B
$850K 0.04%
+200,000
New +$364K
ARCT icon
146
Arcturus Therapeutics
ARCT
$216M
$848K 0.04%
+50,000
New +$872K
LUNG icon
147
CALL
Pulmonx
LUNG
$98.4M
$843K 0.04%
+100,000
New +$951K
PACB icon
148
Pacific Biosciences
PACB
$345M
$818K 0.04%
+100,000
New +$862K
VRTX icon
149
Vertex Pharmaceuticals
VRTX
$133B
$809K 0.04%
2,800
-23,963
-90% -$7.3M
ARWR icon
150
CALL
Arrowhead Research
ARWR
$12.3B
$803K 0.04%
+19,800
New +$656K
4 5
6
7 8

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q4 2022 Portfolio in Review

As of Q4 2022, Pura Vida Investments held 268 positions worth $1.94B, up 12% from $1.73B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Pura Vida Investments deployed $157M of net new capital in Q4 2022, opening 72 new positions and adding to 34 existing holdings. Its largest new stake was Natera: 165,000 shares worth $6.63M.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 35% a quarter earlier, followed by Industrials and Materials.

On the sell side, the largest reduction was United Therapeutics, an estimated $22.4M trimmed.

  • Pura Vida Investments's largest Q4 2022 buy was Natera: 165,000 shares worth $6.63M.
  • Pura Vida Investments added most to Biogen in Q4 2022, an estimated $16.3M increase.
  • Pura Vida Investments's biggest Q4 2022 reduction was United Therapeutics, cutting an estimated $22.4M.
  • Pura Vida Investments fully exited Illumina in Q4 2022, selling an estimated $11.7M.
  • Pura Vida Investments's ten largest holdings make up 38% of its $1.94B portfolio in Q4 2022.
  • Pura Vida Investments opened 72 new positions and closed 76 in Q4 2022.
  • Pura Vida Investments's portfolio value rose 12% quarter-over-quarter to $1.94B.

Based on Pura Vida Investments's 13F filing for Q4 2022, filed 14 Feb 2023.